{
  "id": 16338724,
  "title": "#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial",
  "url": "https://urgent.news/2026/10/24/esmo26-amgens-imdelltra-regimen-more-than-halves-risk-of-death-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-24T14:30:56.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/esmo26-amgens-imdelltra-regimen-more-than-halves-risk-of-death-in-phase-3-lung-cancer-trial/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MADRID — Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi slashed the chances of dying by 58% versus Imfinzi alone in the first-line maintenance setting in certain small cell lung cancer patients, breezing past the benchmark set by ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Cancer Research UK",
        "title": "ESMO 2026: First phase 3 trial results for a personalised cancer vaccine",
        "url": "https://urgent.news/2026/10/23/esmo-2026-first-phase-3-trial-results-for-a-personalised-cancer",
        "published": "2026-10-23T11:23:25.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}